N-(2-(5-methoxy-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide | 847851-58-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(5-methoxy-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide
• 英文别名: N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-phenylbenzamide
• CAS: 847851-58-5
• 化学式: C₂₄H₂₂N₂O₂
• 分子量: 370.451
• InChiKey: DSZNGEKRTSTCNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  54.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-甲氧基色胺 、 联苯-4-甲酰氯 生成 N-(2-(5-methoxy-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide
  参考文献：
  名称：

  Synthesis of benzamide derivatives as TRPV1 antagonists

  摘要：

  From hit compounds identified by high throughput screening (HTS), we have found compound 1 as a lead TRPV1 antagonist and confirmed its potential as a treatment for pain. Compound 1 has led to potent TRPV1 antagonistic benzamide derivatives ((+/-)-2: human IC50 = 23 nM, (+/-)-3: human IC50 = 14 nM in the capsaicin-induced calcium influx assay) containing indole and naphthyl moieties, obtained by elaboration of the tryptamine scaffold or via bioisosteric replacements. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.12.007

文献信息

• NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Griffioen Gerard

  公开号：US20130289033A1

  公开（公告）日：2013-10-31

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R 1 , R 2 , R 4 , R 5 , R 6 , E, n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , B, R 8 , and m are as defined in the claims.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明进一步涉及包括所述新型化合物的药物组合物以及制备所述新型化合物的方法。这些化合物的公式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m如权利要求中所定义。
• [EN] FUNCTIONALIZED AZABORINE COMPOUNDS AND AZABORINE-CONTAINING BIARYLCARBOXAMIDES, AND COMPOSITIONS AND METHODS THEREOF<br/>[FR] COMPOSÉS D'AZABORINE FONCTIONNALISÉS ET BIARYLCARBOXAMIDES CONTENANT DE L'AZABORINE, ET LEURS COMPOSITIONS ET PROCÉDÉS
  申请人：TRUSTEES BOSTON COLLEGE

  公开号：WO2015160688A1

  公开（公告）日：2015-10-22

  The invention provides novel azaborine compounds, methods for their syntheses and functionalization, and various applications thereof. For example, novel azaborine-containing biarylcarboxylic acids and biarylcarboxamides are disclosed herein, which provide the opportunity to be used as therapeutic agents in different diseases. The novel azaborine-containing compounds show unique physical and biological properties when compared to their corresponding all-carbon compounds. Also, disclosed herein are substituted 1,2-dihydro- 1,2-azaborine compounds and methods for making the same including methods for the preparation of various substituted azaborines including alkyl, alkenyl, aryl, nitrile, heteroaryl, and fused ring substituents in the presence of B-H, B-Cl, B-O and N-H bonds from Br-substituted azaborines as well as the synthesis of new fused BN- heterocycles.

  本发明提供了新颖的氮硼因化合物、它们的合成及功能化方法，以及它们在各种应用中的用途。例如，本文公开了含有氮硼因的联芳基羧酸和联芳基酰胺，它们提供了作为不同疾病治疗剂使用的机会。与相应的全碳化合物相比，这些新颖的氮硼因化合物显示出独特的物理和生物学特性。此外，本文还公开了取代的1,2-二氢-1,2-氮硼因化合物及其制备方法，包括制备各种取代的氮硼因的方法，这些取代基包括烷基、烯基、芳基、腈、杂芳基和稠合环取代基，在B-H、B-Cl、B-O和N-H键的存在下，从溴取代的氮硼因出发，以及合成新的稠合BN杂环的方法。
• [EN] NOVEL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX COMPOSÉS POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2012080220A1

  公开（公告）日：2012-06-21

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

  这项发明提供了新颖的化合物，以及这些新颖的化合物用作药物，更具体地用于预防或治疗神经退行性疾病，更具体地说是某些神经系统疾病，例如被统称为tau病变的疾病，以及以细胞毒性α-突触核蛋白淀粉样生成为特征的疾病。本发明还涉及利用这些新颖的化合物制备对治疗这种神经退行性疾病有用的药物。本发明还涉及包括这些新颖化合物的药物组合物，以及这些新颖化合物的制备方法。这些化合物的化学式为(A1)，其中R1、R2、R4、R5、R6、E、n、Y1、Y2、Y3、Y4、Y5、B、R8和m的定义如索赔中所述。
• Compounds for the treatment of neurodegenerative diseases
  申请人：Griffioen Gerard

  公开号：US09284271B2

  公开（公告）日：2016-03-15

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds. The compounds have the formula (A1), wherein R1, R2, R4, R5, R6, E, n, Y1, Y2, Y3, Y4, Y5, B, R8, and m are as defined in the claims.

  本发明提供了新型化合物及其作为药物的使用，更具体地用于预防或治疗神经退行性疾病，更具体地说是某些神经疾病，如被统称为tau病变的疾病和由细胞毒性α-突触蛋白淀积所特征的疾病。本发明还涉及使用所述新型化合物制备用于治疗这些神经退行性疾病的药物。本发明还涉及包括所述新型化合物的制药组合物以及制备所述新型化合物的方法。化合物的化学式为（A1），其中R1，R2，R4，R5，R6，E，n，Y1，Y2，Y3，Y4，Y5，B，R8和m如权利要求所定义。
• N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders
  申请人：Katholieke Universiteit Leuven

  公开号：EP2651887B1

  公开（公告）日：2016-08-24